Celltrion's COVID-19 antibody drug cut recovery time-early study
The result bodes well for Celltrion, which plans to seek conditional approval for the monoclonal antibody treatment, CT-P59, for emergency use by the end of this year in South Korea. In its global Phase 1 trial that enrolled 18 patients with mild symptoms of COVID-19, 15 participants who received the

Full story is loading. Click here if it doesn't...